Efficacy of neuroprotective treatment including pyrimidine nucleotides in secondary uveitic glaucoma
Journal Title: Офтальмологический журнал - Year 2018, Vol 0, Issue 2
Abstract
Background: Secondary glaucoma is found in 18% to 38% of patients with uveitis, and is one of the most severe uveitic complications. The glaucomatous process is characterized by the progressive optic nerve neuropathy. The lack of efficacy of conventional neuroprotective approaches urged us to search for novel medications capable of stabilizing glaucoma. Purpose: To investigate the efficacy of neuroprotective treatment with pyrimidine nucleotides for secondary uveitic glaucoma. Materials and Methods: Patients with secondary uveitic glaucoma were divided into the study group (23 patients; 23 eyes) and the control group (21 patients; 21 eyes). The multicomponent neuroprotective treatment of the study group (but not of the control group) included a direct neuroprotector, Nucleo CMP Forte® drug containing two pyrimidine nucleotides, cytidine 5'-monophosphate and uridine 5'- triphosphate. The group received 2 ml of the drug intramuscularly daily for 10 days, and, thereafter, 2 capsules orally twice daily for 20 days. Each patient underwent visual acuity measurement and perimetry. In addition, phosphene threshold current (PTC) and critical frequency of phosphene (CFP) were determined. Results: Although no improvements in functional characteristics of the visual system were observed in the control group, the use of the pyrimidine nucleotide-containing drug as a component of therapy for uveitic glaucoma contributed to a 39% improvement in visual acuity, 17% increase in total visual field, 22% decrease in PTC, and 23% increase in CFP compared with baseline. Our long-term findings evidence that glaucoma was stabilized with neuroprotective therapy including, in particular, Nucleo CMP Forte, with generally maintained peripapillary RNFL thickness. Conclusion: The use of the pyrimidine nucleotide-containing drug as a component of therapy for uveitic glaucoma promoted an improvement in visual function and contributed to stabilization of glaucoma over 6-8 months
Authors and Affiliations
V. Savko Snr
Keywords
Related Articles
- EP ID EP422113
- DOI 10.31288/oftalmolzh/2018/2/2933
- Views 114
- Downloads 0
Predicting the risk for progression of acquired myopia in school-age children
Background: Prediction of myopia progression in children is of practical relevance. Purpose: To develop a prediction table for comprehensive assessment of the risks for progression of acquired myopia in school-age child...
Surgical management of bilateral congenital coloboma of the iris and congenital cataract
Background. A combined character of a defect, which is congenital coloboma in the presence of congenital cataract, brings up an issue of choosing optimal management to achieve the maximum possible optical functions, prov...
Comparing bioelectrical activity of the central retina among myopic patients operated for rhegmatogenous retinal detachment complicated by choroidal detachment
Background: Rhegmatogenous retinal detachment (RRD) is a serious incapacitating disease requiring surgical treatment. Trophic disturbances in the central and peripheral retina are characteristic for myopia, which is know...
Efficacy of using antibacterial fusidic acid drops in patients with red eye
Introduction. A red eye includes various etiology diseases of the ocular surface (eyelids, conjunctiva, and cornea) as well as of the vascular tract and lacrimal apparatus, the main feature of which is hyperemia of the c...
Visualization of intraocular foreign bodies in the projection of the ciliary body by transpalpebral near-infrared transillumination
Background: Despite advances in intraocular foreign body (IOFB) diagnosis, detecting IOFB is a challenge for the ocular traumatologist. Purpose: To assess the potential of near-infrared transpalpebral transillumination...